Back to News
Market Impact: 0.34

Arvinas, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Source: Nasdaq

Corporate EarningsHealthcare & BiotechCompany Fundamentals

Arvinas reported revenue of $0.5 million for the quarter ended September 30, 2026, down from $41.9 million in the year-earlier quarter. GAAP research and development expenses decreased to $46.9 million; the article provides no comparison figure for that expense.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly negative

Sentiment Score

-0.38

Ticker Sentiment

ARVN-0.55

More News

From AllMind Research

Browse all research